BACKGROUND: Ocular melanoma is the most common primary intraocular malignancy and has a very poor prognosis once liver metastases occur. The aim of this study was to prospectively assess the efficacy and safety of percutaneous hepatic perfusion with melphalan (M-PHP) using the new second-generation (GEN 2) hemofiltration system in patients with ocular melanoma metastases confined to the liver. METHODS: Prospective, single-center, single-arm, phase II study including patients with unresectable ocular melanoma metastases confined to the liver. Treatment consisted of two M-PHP procedures at 6-8 weeks interval. Procedures were performed using the CHEMOSAT (GEN 2) system with 3 mg/kg melphalan. Primary endpoints were overall response rate (ORR) and best overall response (BOR). Secondary endpoints included overall survival (OS), progression-free survival (PFS), hepatic PFS (hPFS), and safety. RESULTS: Sixty-four M-PHP procedures were performed in 35 patients between February 2014 and June 2017. The ORR was 72%. BOR was as follows: complete response in 3%, partial response in 69%, stable disease in 13%, and progressive disease in 16%. There was no treatment-related mortality. Fourteen serious adverse events occurred. At a median follow-up of 19.1 months (range 5.6-69.5), median OS was 19.1 months and was significantly longer in responders than in nonresponders (27.5 vs. 11.9 months, p < 0.001). The 1- and 2-year OS was 77% and 43%, respectively. PFS and hPFS were 7.6 and 11.2 months, respectively. CONCLUSIONS: M-PHP using the GEN 2 filter can achieve a high ORR and prolonged survival in patients with liver-only ocular melanoma metastases.
BACKGROUND:Ocular melanoma is the most common primary intraocular malignancy and has a very poor prognosis once liver metastases occur. The aim of this study was to prospectively assess the efficacy and safety of percutaneous hepatic perfusion with melphalan (M-PHP) using the new second-generation (GEN 2) hemofiltration system in patients with ocular melanoma metastases confined to the liver. METHODS: Prospective, single-center, single-arm, phase II study including patients with unresectable ocular melanoma metastases confined to the liver. Treatment consisted of two M-PHP procedures at 6-8 weeks interval. Procedures were performed using the CHEMOSAT (GEN 2) system with 3 mg/kg melphalan. Primary endpoints were overall response rate (ORR) and best overall response (BOR). Secondary endpoints included overall survival (OS), progression-free survival (PFS), hepatic PFS (hPFS), and safety. RESULTS: Sixty-four M-PHP procedures were performed in 35 patients between February 2014 and June 2017. The ORR was 72%. BOR was as follows: complete response in 3%, partial response in 69%, stable disease in 13%, and progressive disease in 16%. There was no treatment-related mortality. Fourteen serious adverse events occurred. At a median follow-up of 19.1 months (range 5.6-69.5), median OS was 19.1 months and was significantly longer in responders than in nonresponders (27.5 vs. 11.9 months, p < 0.001). The 1- and 2-year OS was 77% and 43%, respectively. PFS and hPFS were 7.6 and 11.2 months, respectively. CONCLUSIONS:M-PHP using the GEN 2 filter can achieve a high ORR and prolonged survival in patients with liver-only ocular melanoma metastases.
Authors: Akira Yamamoto; Inna Chervoneva; Kevin L Sullivan; David J Eschelman; Carin F Gonsalves; Michael J Mastrangelo; David Berd; Jerry A Shields; Carol L Shields; Mizue Terai; Takami Sato Journal: Radiology Date: 2009-07 Impact factor: 11.105
Authors: L Khoja; E G Atenafu; S Suciu; S Leyvraz; T Sato; E Marshall; U Keilholz; L Zimmer; S P Patel; S Piperno-Neumann; J Piulats; T T Kivelä; C Pfoehler; S Bhatia; P Huppert; L B J Van Iersel; I J M De Vries; N Penel; T Vogl; T Cheng; G Fiorentini; F Mouriaux; A Tarhini; P M Patel; R Carvajal; A M Joshua Journal: Ann Oncol Date: 2019-08-01 Impact factor: 32.976
Authors: Carin F Gonsalves; David J Eschelman; Kevin L Sullivan; P Rani Anne; Laura Doyle; Takami Sato Journal: AJR Am J Roentgenol Date: 2011-02 Impact factor: 3.959
Authors: Kashyap Patel; Kevin Sullivan; David Berd; Michael J Mastrangelo; Carol L Shields; Jerry A Shields; Takami Sato Journal: Melanoma Res Date: 2005-08 Impact factor: 3.599
Authors: Saidja L Noter; Joost Rothbarth; Milan E J Pijl; Jan E E Keunen; Henk H Hartgrink; Fred G J Tijl; Peter J K Kuppen; Cornelis J H van de Velde; Rob A E M Tollenaar Journal: Melanoma Res Date: 2004-02 Impact factor: 3.599
Authors: Mark C Burgmans; Eleonora M de Leede; Christian H Martini; Ellen Kapiteijn; Alexander L Vahrmeijer; Arian R van Erkel Journal: Cardiovasc Intervent Radiol Date: 2015-12-30 Impact factor: 2.740
Authors: Kseniya Glinkina; Arwin Groenewoud; Amina F A S Teunisse; B Ewa Snaar-Jagalska; Aart G Jochemsen Journal: Cancers (Basel) Date: 2022-06-29 Impact factor: 6.575
Authors: T Susanna Meijer; Jan H N Dieters; Eleonora M de Leede; Lioe-Fee de Geus-Oei; Jaap Vuijk; Christian H Martini; Arian R van Erkel; Jacob Lutjeboer; Rutger W van der Meer; Fred G J Tijl; Ellen Kapiteijn; Alexander L Vahrmeijer; Mark C Burgmans Journal: PLoS One Date: 2022-01-13 Impact factor: 3.240
Authors: Sachin Modi; Tom Gibson; Ganesh Vigneswaran; Shian Patel; Matthew Wheater; Ioannis Karydis; Sanjay Gupta; Arjun Takhar; Neil Pearce; Christian Ottensmeier; Brian Stedman Journal: Melanoma Res Date: 2022-04-01 Impact factor: 3.199
Authors: T M L Tong; M K van der Kooij; F M Speetjens; A R van Erkel; R W van der Meer; J Lutjeboer; E L van Persijn van Meerten; C H Martini; R W M Zoethout; F G J Tijl; C U Blank; M C Burgmans; E Kapiteijn Journal: Trials Date: 2022-02-13 Impact factor: 2.279
Authors: T M L Tong; M Samim; E Kapiteijn; T S Meijer; F M Speetjens; R Brüning; T H Schroeder; S El-Sanosy; H Maschke; F K Wacker; A Vogel; C L A Dewald; J J Goeman; M C Burgmans Journal: Cardiovasc Intervent Radiol Date: 2022-08-03 Impact factor: 2.797